Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Andrea Mafficini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7471-3121; OpenAlex author ID A5011220308. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 11

  1. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  2. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. Co-author DOI 10.1002/1878-0261.13658↗
  3. The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41417-024-00814-3↗
  4. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  5. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… First author DOI 10.1007/s00428-021-03205-3↗
  6. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Co-author DOI 10.1080/14728222.2022.2021397↗
  7. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Co-author DOI 10.1186/s13046-021-02153-9↗
  8. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Co-author DOI 10.3390/cancers13133119↗
  9. Non-coding regulatory variations: the dark matter of pancreatic cancer genomics. First author DOI 10.1136/gutjnl-2017-314310↗
  10. Splice variants as novel targets in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-017-03354-z↗
  11. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. First author DOI 10.1186/1471-2407-11-448↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aldo Scarpa · 11 shared papers, 2011–2025 · strength 1.36
  2. Rita Teresa Lawlor · 9 shared papers, 2017–2025 · strength 1.16
  3. Claudio Luchini · 7 shared papers, 2021–2025 · strength 0.92
  4. Roberto Salvia · 5 shared papers, 2017–2025 · strength 0.57
  5. Paola Mattiolo · 4 shared papers, 2021–2025 · strength 0.55
  6. Lodewijk A.A. Brosens · 4 shared papers, 2021–2025 · strength 0.55
  7. Giuseppe Malleo · 4 shared papers, 2021–2025 · strength 0.51
  8. Antonio Pea · 4 shared papers, 2021–2025 · strength 0.51
  9. Michèle Milella · 4 shared papers, 2021–2023 · strength 0.51
  10. Vincenzo Corbo · 3 shared papers, 2022–2025 · strength 0.44
  11. Emilia Alors‐Pérez · 3 shared papers, 2021–2024 · strength 0.43
  12. Ricardo Blázquez‐Encinas · 3 shared papers, 2021–2024 · strength 0.43
  13. Justo Pastor Castano · 3 shared papers, 2021–2024 · strength 0.43
  14. Αναστάσιος Γκουντάκος · 2 shared papers, 2023–2025 · strength 0.28
  15. Michele Simbolo · 2 shared papers, 2023–2025 · strength 0.28
  16. Valentyna Kryklyva · 2 shared papers, 2021–2022 · strength 0.27
  17. Nicola Silvestris · 2 shared papers, 2022–2023 · strength 0.24
  18. Giovanni Marchegiani · 2 shared papers, 2021–2022 · strength 0.23
  19. Corinne Bousquet · 1 shared paper, 2024 · strength 0.18
  20. Iranzu González‐Borja · 1 shared paper, 2024 · strength 0.16
  21. Antonio Viúdez · 1 shared paper, 2024 · strength 0.16
  22. Francesca Masetto · 1 shared paper, 2025 · strength 0.16
  23. Jaswinder Singh Samra · 1 shared paper, 2025 · strength 0.16
  24. Kohei Fujikura · 1 shared paper, 2025 · strength 0.16
  25. Amber L. Johns · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.